Medarex Revenue and Competitors
Estimated Revenue & Valuation
- Medarex's estimated annual revenue is currently $18.3M per year.
- Medarex's estimated revenue per employee is $155,000
Employee Data
- Medarex has 118 Employees.
- Medarex grew their employee count by 3% last year.
Medarex Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is Medarex?
Medarex is a biopharmaceutical company focused on the discovery, development, and potential commercialization of fully human antibody-based therapeutics to treat life- threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs.
keywords:N/A
N/A
Total Funding
118
Number of Employees
$18.3M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Medarex News
... as other world leaders in antibody development (such as Amgen, Immunogen, WuXi, Medarex (BMS), Alere (Abbott), BioWa, and Nerviano).
... Katsura Chemical, Lepu Medical, Livanova, Medarex, Medico, Medtronic, Merck, Minsheng Group, Nexus Pharmaceuticals, Nihon Kohden, Oscor,...
Other Companies in Princeton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $26M | 118 | -2% | N/A |
#2 | $17.3M | 119 | -7% | N/A |
#3 | $21.6M | 120 | 1% | N/A |
#4 | $17.5M | 121 | 73% | N/A |
#5 | $17.7M | 122 | -3% | N/A |